A Father's Search for Answers Leads to Astrosalva Therapeutics, a New Biotech for Alexander Disease and cALD
Unravel Biosciences is Astrosalva's founding development partner; Unravel co-founder and CEO Richard Novak, PhD, joins Astrosalva's board of directors
SAN MATEO, Calif., Oct. 29, 2026 /PRNewswire/ -- Astrosalva Therapeutics, Inc. ("Astrosalva"), a privately held, preclinical biotechnology company developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), today announced its launch with Unravel Biosciences, Inc. ("Unravel") as its founding development partner. Richard Novak, PhD, co-founder and CEO of Unravel, has joined Astrosalva's board of directors. Families, clinicians and researchers can sign up for updates at astrosalva.com.
Alexander disease and the cerebral form of adrenoleukodystrophy (cALD) are rare genetic diseases that affect the brain's white matter. The cerebral form affects both children and adults, and in children it can progress rapidly, often leading to total disability within a few years. MedlinePlus puts the prevalence of X-linked adrenoleukodystrophy, the genetic condition behind cALD, at 1 in 15,000 people worldwide, and Ionis Pharmaceuticals estimates that Alexander disease affects about 1 in 1 to 3 million people worldwide. As Astrosalva learned more about the shared challenges faced by families affected by rare neurodegenerative diseases, it expanded its focus to cALD, where the need for new treatment options remains urgent.
"My son Max was seven months old when he was diagnosed with Alexander disease and we were told there was nothing that could be done," said Thomas Wagner, co-founder of Astrosalva. "I read hundreds of research papers and wrote to the scientists who had written them, and many wrote back. Those conversations showed me how much promise there is in the research. Astrosalva exists to turn it into medicines, for Max and for every family facing these diseases."
"Families living with Alexander disease and cALD now have approved treatments, and they still need more, including medicines that are easier to take," said Paul Schmidt, co-founder and CEO of Astrosalva. "After more than 10 years in rare disease, the pattern I keep seeing is promising research that never gets a company built around it. Thomas brought the science, and together we set up this company to turn it into a medicine, with the urgency these families deserve."
"Astrosalva embodies patient-led drug development, which is critical to meeting pressing patient needs," said Richard Novak, PhD, co-founder and CEO of Unravel. "We're pleased to be Astrosalva's founding development partner and bring our experience in rare and complex disease drug development to its programs."
Astrosalva's programs are preclinical, which means there is no active clinical trial or expanded-access program to join. Families, clinicians and researchers can write to [email protected], or sign up for updates at astrosalva.com.
About Astrosalva Therapeutics
Astrosalva Therapeutics is a privately held, preclinical biotechnology company developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Astrosalva was co-founded by Thomas Wagner and Paul Schmidt. Unravel Biosciences, a clinical-stage therapeutics company, is its founding development partner. Paul Schmidt, the company's chief executive officer, has spent nearly 15 years in biopharma, more than 10 of them in rare disease. The company is based in San Mateo, California.
About Unravel Biosciences
Unravel is a clinical-stage therapeutics company that integrates AI systems biology computation with rapid clinical validation of discovered targets. Its proprietary Predictable Medicine™ platform uses primary transcriptomics data to create Living Molecular Twins™ of real patients that can be used to predict therapeutic response. Unravel's platform-discovered therapeutic pipeline spans neurodegenerative, neurodevelopmental, and metabolic disorders.
Media contact
Astrosalva Therapeutics: [email protected]
Unravel Biosciences: [email protected]
SOURCE Astrosalva Therapeutics, Inc.
Share this article